BF.7 Omicron subvariant (BA.5.2.1.7) posing fears of a rise in COVID-19 cases again: a critical appraisal and salient counteracting strategies.
作者信息
Dhama Kuldeep, Tuglo Lawrence S, Chakraborty Chiranjib, Saikumar Gutulla
机构信息
Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, Uttar Pradesh.
Department of Nutrition and Dietetics, School of Allied Health Sciences, University of Health and Allied Sciences, Ho, Ghana.
出版信息
Int J Surg. 2023 Apr 1;109(4):1058-1059. doi: 10.1097/JS9.0000000000000286.
Abstract
摘要
相似文献
1
BF.7 Omicron subvariant (BA.5.2.1.7) posing fears of a rise in COVID-19 cases again: a critical appraisal and salient counteracting strategies.BF.7奥密克戎亚型毒株（BA.5.2.1.7）再次引发对新冠病例数上升的担忧：批判性评估及显著的应对策略
Int J Surg. 2023 Apr 1;109(4):1058-1059. doi: 10.1097/JS9.0000000000000286.
2
A commentary on 'BF.7 Omicron subvariant (BA.5.2.1.7) posing fears of a rise in COVID-19 cases again: a critical appraisal and salient counteracting strategies'.关于“BF.7奥密克戎亚变体（BA.5.2.1.7）引发对新冠病例再次上升的担忧：批判性评估及显著应对策略”的评论
Int J Surg. 2024 Jan 1;110(1):582-583. doi: 10.1097/JS9.0000000000000766.
3
Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread.社论：奥密克戎 SARS-CoV-2 的 XBB.1.5（“Kraken”）亚变体及其快速全球传播。
Med Sci Monit. 2023 Feb 1;29:e939580. doi: 10.12659/MSM.939580.
4
Risk evaluation and mitigation strategies for newly detected SARS-CoV-2 Omicron BF.7 subvariant: A brief report.新发现的严重急性呼吸综合征冠状病毒2奥密克戎BF.7亚变体的风险评估与缓解策略：简要报告
Health Sci Rep. 2023 Mar 2;6(3):e1127. doi: 10.1002/hsr2.1127. eCollection 2023 Mar.
5
Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.丹麦全国性观察研究：与 SARS-CoV-2 奥密克戎亚变体 BA.2.86 和后代 JN.1 相关的相对疫苗保护、疾病严重程度和症状。
Lancet Infect Dis. 2024 Sep;24(9):964-973. doi: 10.1016/S1473-3099(24)00220-2. Epub 2024 May 15.
6
Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.新英格兰地区估计 SARS-CoV-2 奥密克戎 BA.2 亚变种的严重程度。
JAMA Netw Open. 2022 Oct 3;5(10):e2238354. doi: 10.1001/jamanetworkopen.2022.38354.
7
Invalidity of JRS atypical pneumonia prediction score in Omicron variant of COVID-19 pneumonia.JRS 非典型性肺炎预测评分在 COVID-19 奥密克戎变异株肺炎中的无效性。
Respir Investig. 2024 May;62(3):384-387. doi: 10.1016/j.resinv.2024.02.010. Epub 2024 Mar 7.
8
Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections.中和抗体疗法索特罗维单抗治疗 SARS-CoV-2 奥密克戎 BA.1 和 BA.2 亚变种感染患者的临床疗效。
Viruses. 2023 May 31;15(6):1300. doi: 10.3390/v15061300.
9
Clinical virology and effect of Covid-19 vaccination and monoclonal antibodies against highly infectious SARS- CoV-2 omicron sub variant BF.7 (BA.5.2.1.7): A systematic review.临床病毒学以及 COVID-19 疫苗和单克隆抗体对高传染性 SARS-CoV-2 奥密克戎变异株 BF.7（BA.5.2.1.7）的影响：系统评价。
Virology. 2023 Jul;584:38-43. doi: 10.1016/j.virol.2023.04.007. Epub 2023 May 19.
10
A meta-analysis on the immunogenicity of prototype, monovalent-adapted and bivalent vaccines against SARS-CoV-2 wildtype, Omicron BA.1 and Omicron BA.4/5 in healthy adults.一项关于原型疫苗、单价适配疫苗和二价疫苗针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）野生型、奥密克戎BA.1和奥密克戎BA.4/5在健康成年人中的免疫原性的荟萃分析。
Virology. 2025 May;606:110509. doi: 10.1016/j.virol.2025.110509. Epub 2025 Mar 19.
引用本文的文献
1
Retrospective study about clinical severity and epidemiological analysis of the COVID-19 Omicron subvariant lineage-infected patients in Hohhot, China.关于呼和浩特市感染新冠病毒奥密克戎变异株的 COVID-19 患者临床严重程度和流行病学分析的回顾性研究。
BMC Infect Dis. 2024 Feb 15;24(1):206. doi: 10.1186/s12879-024-09084-8.
2
COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2.孕期接种新冠病毒二价加强疫苗：母体和新生儿对奥密克戎BA.5、BQ.1、BF.7和XBB.1.5型严重急性呼吸综合征冠状病毒2的抗体反应
Vaccines (Basel). 2023 Aug 28;11(9):1425. doi: 10.3390/vaccines11091425.
Zotero 插件